2025
Serotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With Takotsubo Cardiomyopathy.
Shamaki G, Anuforo A, Safiriyu I, Corteville D, Sanghavi M, Shah S, Clark K. Serotonin Norepinephrine Reuptake Inhibitor Is Associated With Lower Mortality Among Patients Presenting With Takotsubo Cardiomyopathy. Journal Of The American Heart Association 2025, 14: e037951. PMID: 40551298, DOI: 10.1161/jaha.124.037951.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsDiagnosis of takotsubo cardiomyopathyTakotsubo cardiomyopathyPropensity score matchingReuptake inhibitorsClinical outcomes of patientsNorepinephrine reuptake inhibitorsReuptake of serotoninScore matchingOutcomes of patientsOpioid-related disordersCocaine-related disordersAssociated with lower mortalityLower mortalityTriNetX Research NetworkTreatment of depressionAssociated with lowered mortalityAcute myocardial infarctionNeuropathic painPresynaptic reuptakeClinical outcomesCardiac arrestPrimary outcomeSecondary outcomesVentricular fibrillationStreamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis
Zeidan A, Yu R, Wang Y, Lan Z, Grinblatt D, Elsouda D, Spalding J, Block A, Touya M, Walker M, Pandya B. Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis. Acta Haematologica 2025, 1-12. PMID: 40228486, PMCID: PMC12112888, DOI: 10.1159/000545384.Peer-Reviewed Original ResearchAcute myeloid leukemiaReal-world overall survivalAcute myeloid leukemia diagnosisReal-world time to next treatmentTreatment patternsFLT3-TKIMyeloid leukemiaClinical outcomesMedian real-world overall survivalTime to next treatmentClinical outcomes of patientsFLT3 tyrosine kinase inhibitorsReal-world treatment patternsAcute myeloid leukemia patientsFMS-like tyrosine kinase 3R/R AML patientsHigh-intensity chemotherapyOutcomes of patientsRetrospective cohort studyTyrosine kinase 3Retrospective longitudinal studyFirst relapseOverall survivalAML patientsFLT3 mutationsSafety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Nassar A, Alaiwi S, Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman R, Johnson D, Grynberg S, Shapira R, Kwan J, Woodford R, Long G, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang E, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Herrera M, Foderaro S, Nana F, Kim C, Sackstein P, Parikh K, Desai A, Smith C, Cortellini A, Pinato D, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Gallegos J, Trent J, Nusrat S, Malvar C, McKay R, Neilan T, Choueiri T, Naqash A. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal For ImmunoTherapy Of Cancer 2025, 13: e009364. PMID: 40032601, PMCID: PMC11877189, DOI: 10.1136/jitc-2024-009364.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitor initiationImmune checkpoint inhibitorsTreatment-related adverse eventsObjective response rateProgression-free survivalCardiac metastasisOverall survivalRetrospective studyAnti-cytotoxic T-lymphocyte antigen 4Dose of immune checkpoint inhibitorsEfficacy of immune checkpoint therapyAnti-programmed death-1International multicenter retrospective studyMulticenter international retrospective studyT-lymphocyte antigen-4Non-small cell lung cancerMedian follow-up timeClinical outcomes of patientsICI-based regimensMultiple cardiac metastasesSolid Tumors V.1.1Immune checkpoint therapyResponse Evaluation CriteriaInternational retrospective studyMulticenter retrospective studyWorse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation
Makarova E, Fan X, Farooqi I, Bakhl K, Murphy T, Stonesifer E, Faust A. Worse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation. Journal Of Liver Transplantation 2025, 17: 100257. DOI: 10.1016/j.liver.2024.100257.Peer-Reviewed Original ResearchTrans arterial chemoembolizationDecompensated liver functionHepatocellular carcinomaLiver functionLiver transplantationClinical outcomesRetrospective cohort study of patientsClinical outcomes of patientsWorsening of liver functionCohort study of patientsCompensated liver functionOutcomes of patientsCohort of patientsRetrospective cohort studyStudy of patientsStatistically significant differenceLocoregional therapyArterial chemoembolizationDecompensated cirrhosisPoor outcomePrimary statistical analysisPatientsCirrhosisTransplantationSignificant differenceTreatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)
Richard E, Desai N, Willey V, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng C, Oberprieler N. Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS). Pragmatic And Observational Research 2025, 16: 27-37. PMID: 40034401, PMCID: PMC11873017, DOI: 10.2147/por.s489791.Peer-Reviewed Original ResearchSteroidal mineralocorticoid receptor antagonistsChronic kidney diseaseMineralocorticoid receptor antagonistsOdds of discontinuationAdverse eventsClinical outcomesTreatment patternsDocumented HFReceptor antagonistHeart failureRate of treatment discontinuationComorbidity burdenClinical outcomes of patientsAnalysis of treatment patternsDays of discontinuationOutcomes of patientsRetrospective cohort studyHealth plan disenrollmentHeightened cardiovascular riskMultivariate logistic regressionDays of initiationCardiologist prescribingCohort of adultsRestarting treatmentTreatment discontinuationP-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics
Kumar P, Rolle C, Emu B, Henry Z, Martorell C, McKinnon J, Slim J, Cash R, Anstett K. P-565. A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics. Open Forum Infectious Diseases 2025, 12: ofae631.763. PMCID: PMC11778372, DOI: 10.1093/ofid/ofae631.763.Peer-Reviewed Original ResearchJournal of Antimicrobial ChemotherapyBaseline characteristicsViral loadMultidrug resistanceAntimicrobial chemotherapyCohort 2Maintenance of virologic suppressionHigher HIV viral loadClinical outcomes of patientsExposure to antiretroviralsGenotypic sensitivity scoreCD4 cell countHIV viral loadCD4 T cellsOutcomes of patientsLong-term efficacyRetrospective observational studyHigh viral loadLong-term useVirologic suppressionInfusion reactionsStudy designT cellsSafety profileClinical outcomes
2024
Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections
Shah S, Adams K, Clarke L, Ludwig J, McManus D, Nguyen M, Topal J, Shields R. Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections. International Journal Of Antimicrobial Agents 2024, 65: 107403. PMID: 39667533, DOI: 10.1016/j.ijantimicag.2024.107403.Peer-Reviewed Original ResearchClinical failureDosing strategiesClinical outcomesIncreased risk of clinical failureRetrospective chart review of adult patientsChart review of adult patientsReview of adult patientsRate of clinical failureClinical outcomes of patientsRisk of clinical failureAssociated with worse outcomesOutcomes of patientsRetrospective chart reviewBloodstream infectionsMetronidazole doseAdult patientsWorse outcomesIncreased riskMetronidazolePatientsInclusion criteriaBacteroides sppBacteremiaDoseMortalityPatterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy
Nakashima J, Khatri V, Cruz-Chamorro R, Zhou J, Patra P, Gaballa S, Khimani F, Mirza S, Shah B, Saeed H, Chavez J, Locke F, Nishihori T, Liu H, Dong N, Lazaryan A, Robinson T, Freeman C, Jain M, Figura N. Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e646-e647. DOI: 10.1016/j.ijrobp.2024.07.1421.Peer-Reviewed Original ResearchLarge B-cell lymphomaSecondary CNS lymphomaB-cell lymphomaCNS failureCNS recurrenceCNS diseaseCNS lymphomaCAR-TOverall survivalBridging therapyCNS diagnosisRelapsed/refractory large B-cell lymphomaChimeric antigen receptor T cellsCAR-T cell trialsPattern of failure analysisCAR-T cell therapyMedian age of patientsClinical outcomes of patientsCNS-only progressionSystemic disease recurrenceT-cell therapyCAR-T therapyCytokine-release syndromePatterns of recurrenceKaplan-Meier methodRight Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella
Rommel K, Bonnet G, Bellumkonda L, Lansky A, Zhao D, Thompson J, Zhang Y, Redfors B, Lurz P, Granada J, Bharadwaj A, Basir M, O'Neill W, Burkhoff D. Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella. Journal Of Cardiac Failure 2024, 30: 1244-1254. PMID: 39389734, DOI: 10.1016/j.cardfail.2024.08.001.Peer-Reviewed Original ResearchConceptsRight ventricular dysfunctionHigh-risk percutaneous coronary interventionVentricular dysfunctionAssociated with right ventricular dysfunctionTricuspid annular plane systolic excursionConcomitant right ventricular dysfunctionLower left ventricular ejection fractionUnfavorable long-term prognosisAnnular plane systolic excursionClinical outcomes of patientsAbsence of right ventricular dysfunctionImpella supportPredictor of 1-year mortalityMultivariate Cox regression analysisIncidence of hypotensive episodesEchocardiography core laboratorySevere RV dilatationBlood urea nitrogen levelsRV function assessmentVentricular ejection fractionOutcomes of patientsRates of in-hospital mortalityHigher blood urea nitrogen levelsLong-term prognosisProportion of patientsClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, 79: 2017-2021. PMID: 38958234, PMCID: PMC12102595, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefitImmune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer
Michikawa C, Gleber-Netto F, Pickering C, Rao X, Wang J, Sikora A, Myers J, Frederick M. Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer. Oral Oncology 2024, 153: 106729. PMID: 38663156, DOI: 10.1016/j.oraloncology.2024.106729.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaAssociated with clinical outcomesExtranodal extensionLymph node metastasisImmune infiltrationImmune infiltration statusOverall survivalPrimary tumorNode metastasisOral cancerInfiltration statusClinical outcomes of OSCC patientsExtension of lymph node metastasesAssociated with clinical outcomes of patientsAssociated with OS rateLocally advanced oral cancerClinical outcomes of patientsOutcome of OSCC patientsAssociated with poor overall survivalImmune infiltration of tumorsLow immune infiltrationNode negative tumorsAdvanced oral cancerHuman papillomavirus-negativeInfiltration of tumorsClinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas A Multicenter Retrospective Study
Nassar A, El-Am E, Denu R, Alaiwi S, Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Farhat E, Williams J, Collins J, Al-Hader A, McKay R, Malvar C, Sabra M, Zhong C, Alam R, Chehab O, Lima J, Phan M, Pria H, Trevino A, Neilan T, Kwan J, Ravi V, Deshpande H, Demetri G, Choueiri T, Naqash A. Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas A Multicenter Retrospective Study. JACC CardioOncology 2024, 6: 71-79. PMID: 38510282, PMCID: PMC10950431, DOI: 10.1016/j.jaccao.2023.11.007.Peer-Reviewed Original ResearchMedian progression-free survivalProgression-free survivalImmune checkpoint inhibitorsSoft tissue sarcomasOverall survivalMedian OSTissue sarcomasClinical outcomesCommon Terminology Criteria for Adverse Events versionTreatment-related adverse eventsClinical outcomes of patientsMulti-institutional cohort studyResponse rateICI-based regimensObjective response rateSolid Tumors versionAdverse Events versionLocally advanced diseaseResponse Evaluation CriteriaImmunotherapy-treated patientsSecond-line therapyEstimate overall survivalFirst-line therapyMulticenter retrospective studyKaplan-Meier method
2023
Abstract 93: An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and therapy resistance
Mu P, Li X, Wang Y, Wang T, Deng S. Abstract 93: An endogenous molecular brake preventing APOBEC-driven tumor mutational burden, heterogeneity and therapy resistance. Cancer Research 2023, 83: 93-93. DOI: 10.1158/1538-7445.am2023-93.Peer-Reviewed Original ResearchTumor mutational burdenTherapy resistanceMutational burdenMolecular brakeSingle cell RNA-seqDriver mutationsDrivers of mutagenesisAmerican Association for Cancer Research annual meetingsClinical outcomes of patientsCRISPR library screensRNA-seqExome-sequencingScRNA-seqOutcomes of patientsLibrary screeningFunctional screeningNon-malignant cellsCell-intrinsic mechanismsPromote heterogeneityMutagenesisMutated genesAPOBEC proteinsMutational signaturesMutationsPotential therapeutic target
2022
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors
Mellgard G, Patel V, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Cancer Research And Clinical Oncology 2022, 149: 2833-2841. PMID: 35788726, PMCID: PMC10739778, DOI: 10.1007/s00432-022-04159-y.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeClinical activity of immune checkpoint blockadeAdvanced solid tumorsOverall survivalT cell activationClinical outcomesSolid tumorsCD8+ T cell activationClinical activityClinical outcomes of patientsAdrenergic signalingAntitumor immune activityPharmacological beta-blockadeUrothelial carcinoma cohortImmune checkpoint inhibitorsInfluence overall survivalCox proportional hazards regression modelsDuration of therapyAssociation of OSOutcomes of patientsBeta-blocker useDisease control statusProportional hazards regression modelsBeta-adrenergic signalingInhibited tumor growth
2020
Clinical characteristics and outcomes of diabetics hospitalized for COVID-19 infection: a single-centered, retrospective, observational study
Mansour A, Sajjadi-Jazi S, Kasaeian A, Khosravi B, Sorouri M, Azizi F, Rajabi Z, Motamedi F, Sirusbakht A, Eslahi M, Mojtabbavi H, Sima A, Radmard A, Mohajeri-Tehrani M, Abdollahi M. Clinical characteristics and outcomes of diabetics hospitalized for COVID-19 infection: a single-centered, retrospective, observational study. EXCLI Journal 2020, 19: 1533-1543. PMID: 33343270, PMCID: PMC7744965, DOI: 10.17179/excli2020-2988.Peer-Reviewed Original ResearchBody mass indexDiabetes mellitusBlood urea nitrogenSystolic blood pressureCOVID-19 infectionClinical characteristicsLow estimated glomerular filtration rateClinical outcomes of patientsObservational studyBlood sugarOutcomes of COVID-19 infectionAssociated with worse outcomesAssociation of diabetes mellitusElevated blood urea nitrogenOutcomes of hospitalized COVID-19 patientsOutcomes of patientsElevated systolic blood pressureGlomerular filtration rateAssociation of DMSevere outcomes of COVID-19 infectionCOVID-19 infection severityCOVID-19 patientsElevated blood sugarOutcomes of diabetesSingle-centerEffect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
Patel V, Qin Q, Wang B, Gogerly-Moragoda M, Mellgard G, Zhong X, Parikh A, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Clinical Oncology 2020, 38: e15068-e15068. DOI: 10.1200/jco.2020.38.15_suppl.e15068.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsDisease control rateClinical activity of immune checkpoint inhibitorsActivity of immune checkpoint inhibitorsAdvanced solid tumorsBeta blockersSolid tumorsCheckpoint inhibitorsDose of immune checkpoint inhibitorsCD8+ T cell activationClinical activityImproved disease control rateClinical outcomes of patientsAntitumor immune activityPharmacological beta-blockadeRadiographic complete responseEffects of beta blockersECOG performance statusLocation of metastasesOutcomes of patientsBeta-blocker useT cell activationInhibited tumor growthMultivariate logistic regression modelStable diseaseClinical Outcomes Following Biologically Enhanced Patch Augmentation Repair as a Salvage Procedure for Revision Massive Rotator Cuff Tears
Muench L, Kia C, Jerliu A, Williams A, Berthold D, Cote M, McCarthy M, Arciero R, Mazzocca A. Clinical Outcomes Following Biologically Enhanced Patch Augmentation Repair as a Salvage Procedure for Revision Massive Rotator Cuff Tears. Arthroscopy The Journal Of Arthroscopic And Related Surgery 2020, 36: 1542-1551. PMID: 32241704, DOI: 10.1016/j.arthro.2020.02.006.Peer-Reviewed Original ResearchConceptsAmerican Shoulder and Elbow SurgeonsPatient acceptable symptomatic statePatient acceptable symptomatic state criteriaConcentrated bone marrow aspirateSimple Shoulder TestMinimal Clinically Important DifferenceRotator cuff tearsClinically Important DifferenceMassive rotator cuff tearsAugmented repairShoulder TestClinical successClinical outcomesPostoperative Single Assessment Numerical Evaluation scoresFollow-upCuff tearsAmerican Shoulder and Elbow Surgeons scoreSingle Assessment Numeric Evaluation scoreClinical outcomes of patientsMean American Shoulder and Elbow SurgeonsImportant differenceOutcomes of patientsBone marrow aspirateDay of surgeryPlatelet-rich plasma
2017
Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit
Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye S, Tunariu N, Banerji U, de Bono J, Lopez J. Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. Clinical Oncology 2017, 30: 185-191. PMID: 29224898, DOI: 10.1016/j.clon.2017.11.011.Peer-Reviewed Original ResearchConceptsAdvanced biliary tract carcinomaPhase I clinical trialPhase I unitABC patientsAdvanced biliary tract cancerMolecular characterisation of tumoursClinical outcomes of patientsClinical benefit rateBiliary tract carcinomaBiliary tract cancerComprehensive molecular profilingPhase I trialOutcomes of patientsCharacterisation of tumoursStable diseaseI unitsAdvanced diseaseI trialBenefit rateTargeted therapyTreatment detailsTrial discontinuationExceptional respondersPTEN lossClinical outcomesAbstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit
Lim J, Harris S, Ameratunga M, Sundar R, Ang J, Collins D, Chénard-Poirier M, Garces A, Kaye S, Lopez J, Banerji U, Bono J, Yap T. Abstract 3081: Precision medicine for patients with advanced small cell lung cancer treated with novel therapeutic agents in a phase I clinical trials unit. Cancer Research 2017, 77: 3081-3081. DOI: 10.1158/1538-7445.am2017-3081.Peer-Reviewed Original ResearchSmall cell lung cancerAdvanced small cell lung cancerNovel therapeutic agentsRECIST SDStable diseasePD-1Partial responsePARP inhibitorsNovel therapiesAmerican Association for Cancer Research annual meetingsNext generation sequencingTherapeutic agentsSignals of antitumor activityNo dose limiting toxicitiesDNA damage repairClinical outcomes of patientsResponse to novel therapiesPD-1 inhibitorsPlatinum-sensitive diseaseRECIST partial responseRECIST stable diseaseDose-limiting toxicityTargeted next generation sequencingTumor molecular profilingPhase I trial
2015
Early and late clinical outcomes after saphenous vein graft treatment with MGuardTM stents vs. drug-eluting stents
da Silva D, da Costa J, de Castro Filho A, Staico R, Costa R, Moreira A, Siqueira D, Chamié D, Centemero M, Maldonado G, Cano M, Tanajura L, Chaves Á, Feres F, Abizaid A, Sousa A, Sousa J. Early and late clinical outcomes after saphenous vein graft treatment with MGuardTM stents vs. drug-eluting stents. Journal Of Transcatheter Interventions 2015, 23: 251-255. DOI: 10.1016/j.rbciev.2017.02.007.Peer-Reviewed Original ResearchSaphenous vein graftsPercutaneous coronary interventionTarget lesion revascularizationClinical outcomesLesion revascularizationClinical outcomes of patientsDES groupRate of target lesion revascularizationOutcomes of patientsCohort of patientsAdverse cardiovascular eventsSVG treatmentSaphenous vein graft lesionsTreated with DESProportion of womenEmbolization of fragmentsTertiary centerRetrospective studyMACE rateAngiographic successCardiovascular eventsLow incidencePeriprocedural infarctionCoronary interventionVein grafts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply